

[LF 474]

AUGUST 2014

Sub. Code: 1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY
AND PANCREATIC DISEASES**

Q. P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

Answer ALL questions in the same order.

I. Elaborate on:

(2 x 15 = 30)

1. Discuss in detail about Hepatitis – B virus variants and its clinical significance.
2. Discuss in detail about etiology, pathogenesis and management of Recurrent acute pancreatitis.

II. Write notes on:

(10 x 7 = 70)

1. Transient elastography.
2. Genetics of alcoholic pancreatitis.
3. AIDS cholangiopathy.
4. Neurologic complications after Liver transplantation.
5. Strategies to reduce hepatitis C virus recurrence after Liver transplantation.
6. Hepatitis – E vaccine.
7. Post cholecystectomy syndrome.
8. MELD exception scores.
9. New options of cholangioscopy.
10. Ribavirin analogs.

[LH 474]

AUGUST 2015

Sub. Code: 1474

D.M. – HEPATOLOGY

**PAPER IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC DISEASES**

Q.P. Code : 161474

Time : Three Hours

Maximum : 100 marks

Answer ALL questions

I. Elaborate on:

(2 x 15 = 30)

1. Discuss in detail: complications encountered in the immediate post transplant period – diagnosis and management.
2. Discuss the risk factors and pathophysiology of drug induced liver disease (DILI).
How will you manage antituberculous therapy related hepatotoxicity?

II. Write notes on :

(10 x 7 = 70)

1. Thromboelastograph – applications.
2. Bariatric surgery for treatment of NAFLD.
3. Cullin 7.
4. Newer drugs to treat hepatitis C.
5. Eosinophilic cholangitis.
6. Balloon Occluded Retrograde Transvenous Obliteration in hepatology.
7. Hepatic Hydatid.
8. Chronic liver disease Associated Immune Deficiency Syndrome.
9. Applications of EUS (endosonography) in hepatology.
10. Splenic stiffness.

(LJ 474)

AUGUST 2016

Sub. Code:1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P.Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Hepatorenal syndrome : definition, types, diagnosis and management.
2. Portopulmonary hypertension – definition, pathogenesis, management.

II. Write notes on:

(10 x 7 = 70)

1. Hepatitis E vaccine.
2. Ethical issues in live – donor liver transplantation.
3. Mallory Hyaline bodies on Liver biopsy.
4. Genetic testing in liver disease.
5. Prevention of Hepatitis viral infections after needle stick injuries.
6. Polycystic liver disease – treatment.
7. Sub-acute hepatic failure.
8. Management of drug – resistant spontaneous bacterial peritonitis.
9. Stem cell therapy in liver diseases.
10. Pathogenesis of NAFLD.

(LL 474)

AUGUST 2017

Sub. Code:1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P.Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Discuss in detail about the etiology and recent concepts in management of Acute liver failure.
2. Discuss in detail about etiopathogenesis, clinical features and management of Sphincter of Oddi dysfunction.

II. Write notes on: **(10 x 7 = 70)**

1. TARE.
2. Pancreatic islet cell transplantation.
3. Boceprevir.
4. Endoscopic treatment in chronic pancreatitis.
5. Recent concepts in Acute fatty liver of pregnancy.
6. Ischaemic cholangiopathy.
7. Drug induced auto immune liver disease.
8. Disease modifying agents in Primary biliary cirrhosis.
9. Hepatic artery thrombosis.
10. Nutritional support in acute pancreatitis.

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P.Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Discuss in detail about the role of Endoscopic ultrasound in hepatobiliary and pancreatic diseases.
2. Discuss in detail about the Hepato-biliary manifestations of HIV infection.

II. Write notes on:

(10 x 7 = 70)

1. Haemosuccus pancreaticus.
2. Multimodality therapy for pancreatic carcinoma.
3. Recent advances in biliary stents.
4. Hepatic osteodystrophy.
5. Auxiliary liver transplantation.
6. Aquaretics.
7. Liver transplantation beyond MILAN criteria.
8. Velpatasvir.
9. Noval genetic markers in NAFLD.
10. Acute hepatitis C: Current status and remaining challenges.

(LP 474)

AUGUST 2019

Sub. Code: 1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Discuss in detail: Applications of Interventional Radiology in the management of chronic liver disease and its complications.
2. Discuss on the surgical aspects of Liver transplantation. What a hepatologist should know?

II. Write notes on: **(10 x 7 = 70)**

1. Mitochondrial liver disorders.
2. Potential treatment options in NAFLD (Non-alcoholic fatty liver disease).
3. Carvidelol.
4. Acoustic Radiation Forced Impulse.
5. Management of Splenic artery aneurysm in chronic liver disease.
6. Immunohistochemistry in Hepatocellular carcinoma.
7. Probiotics in Hepatology.
8. NAFLD and Hepatocellular carcinoma.
9. Oral treatment of Hepatitis C.
10. IL – 2 Receptor blocker in liver transplantation.

(DM 0221)

FEBRUARY 2021

Sub. Code: 1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: (2 x 15 = 30)

1. Complications seen in the first week after liver transplantation.
2. Involvement of liver, biliary tree and pancreas in IgG4 related disease.

II. Write notes on: (10 x 7 = 70)

1. Co-Infection with Hepatitis B and HIV infections : management.
2. Lean NASH (Non Alcoholic Hepatitis): Pathogenesis and treatment.
3. Role of Endosonography in Hepatobiliary Diseases.
4. Bariatric Surgery in patient with NAFLD (Non Alcoholic Fatty Liver Disease) Cirrhosis.
5. Immune Checkpoint Inhibitors to treat Hepatocellular Carcinoma.
6. Hepatocyte Transplantation.
7. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Surgery.
8. Indications for Liver Transplantation to treat Hepatocellular Carcinoma.
9. Portopulmonary Hypertension : Pathogenesis and management.
10. Spontaneous bacterial peritonitis caused by multi-drug resistant organisms.

(DM 0821)

AUGUST 2021

Sub. Code: 1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on:

(2 x 15 = 30)

1. Post transplant lympho proliferative disease: etiology / diagnosis / management.
2. Lean NASH (non alcoholic steatohepatitis).

II. Write notes on:

(10 x 7 = 70)

1. Therapeutic plasma exchange to treat liver failure.
2. COVID-19 and liver diseases.
3. Balloon occluded retrograde transvenous obliteration of gastric varices.
4. How to diagnose IgG4 related disease of pancreas or biliary tree.
5. Severe acute liver injury: causes, management.
6. Domino liver transplantation.
7. Portal hypertensive biliopathy.
8. Midodrine: mechanism of action, indications for use, side effects.
9. Post transplant CMV infection management.
10. Curative therapies for hepatocellular carcinoma.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[DM 0822]

AUGUST 2022

Sub. Code :1474

D.M. – HEPATOLOGY

**Paper IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Discuss in detail the Etiopathogenesis, diagnostic criteria and management of MAFLD.
2. Approach to bacterial infections and prevalence of multidrug – resistant bacteria in hospitalized patients with liver cirrhosis.

II. Write notes on: **(10 x 7 = 70)**

1. Cholangioscopy.
2. Hyponatremia in Cirrhosis – Clinical Manifestations and Management.
3. Diagnosis of Sarcopenia in patients with cirrhosis.
4. Liver transplant outcome in India.
5. Endohepatology : current status and perspectives.
6. Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma.
7. Non-invasive methods for iron overload evaluation in dysmetabolic patients.
8. Endoscopic advances in management of pancreatic cancer.
9. Chronic Hepatitis B in India.
10. EUS criteria for diagnosis of chronic pancreatitis.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[DM 0124]

JANUARY 2024

Sub. Code :1474

D.M. – HEPATOLOGY

**PAPER IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Nutrition Management Strategies for Nonalcoholic Fatty Liver Disease: Treatment and Preventions.
2. Palliative Interventions in patients with cirrhosis with refractory ascites and Hepatic Hydrothorax: Who, What, and When?

II. Write notes on: **(10 x 7 = 70)**

1. Parenteral Nutrition–Associated Liver Disease.
2. Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.
3. COVID-19 management of decompensated cirrhosis and liver transplant recipients.
4. Management of Direct-Acting Antiviral Failures.
5. Kernicterus.
6. What is Gallstone Ileus? Discuss briefly the management of this condition.
7. Auto immune pancreatitis- simplified criteria for diagnosis.
8. Mention various modalities of diagnosing Biliary microlithiasis.
9. Diagnosis and management of Hilar Cholangiocarcinoma.
10. Mention the classifications and briefly outline the management of Mirizzi's syndrome.

THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY

[DM 0225]

FEBRUARY 2025

Sub. Code :1474

D.M. – HEPATOLOGY

**PAPER IV – RECENT ADVANCES IN HEPATOBILIARY AND
PANCREATIC SYSTEMS**

Q.P. Code: 161474

Time: Three Hours

Maximum: 100 Marks

I. Elaborate on: **(2 x 15 = 30)**

1. Hepatitis C infection in patients with chronic kidney disease on dialysis: investigations, treatment, implications for kidney transplantation.
2. Transient liver elastography inpatient with portal hypertension.

II. Write notes on: **(10 x 7 = 70)**

1. Newer anti – hepatitis B medicines.
2. Stereotactic ablative body radiotherapy for hepatocellular carcinoma.
3. Multi-drug resistant bacterial infections in patients with cirrhosis.
4. Advances in management of rodenticidal hepatotoxicity.
5. Managing liver secondaries from colonic primary malignancy.
6. Needlestick exposure in health care work – clinical approach.
7. Cholestasis of pregnancy.
8. Plasma exchange to treat acute liver failure.
9. Hepatocellular carcinoma: how to assess response to treatment.
10. Use of midodrine in patients with liver disease.
